Keywords: Agennix, talactoferrin, Fund raising, Cancer, Sepsis

Positive outlook seen for Agennix’ talactoferrin in cancer and sepsis treatment, but firm needs to raise funds, say analysts

Article | 01 April 2010

Print This

German drug developer Agennix is developing talactoferrin, a recombinant version of the human milk protein, lactoferrin, for the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in